Objective. To compare the accuracy of serum calprotectin levels, CRP and ESR in stratifying disease activity in RA patients receiving tocilizumab (TCZ).
Introduction
Tocilizumab (TCZ) is a humanized antiIL-6 receptor mAb approved for use in RA. TCZ has demonstrated efficacy in controlling the signs and symptoms of RA, beneficial effects on radiographic progression and a significant improvement in patient quality of life [13] . TCZ inhibits stimuli to hepatocytes via IL-6 [4] , dramatically improving the acute phase response (APR), including CRP serum levels and ESR, which form part of composite disease activity indices and response criteria in RA [5] , leading to a possible overestimation of the response rate, especially when the DAS28 is used [6] . Therefore, CRP and ESR may not be accurate biomarkers for assessing disease activity in patients receiving TCZ.
Recently, calprotectin (S100A8 and S100A9), a member of the S100 protein family, has been identified as an important endogenous damage-associated molecular pattern molecule that is released by activated phagocytes and recognized by toll-like receptor 4 on multiple inflammatory cell types, such as monocytes and granulocytes [7] . Calprotectin has strong pro-inflammatory effects, and its levels reflect local ongoing inflammation rather than a systemic inflammatory response, due to its release at local inflammation sites [8] . High calprotectin levels have been found in SF and serum from RA patients [9] , and correlate with disease activity [10] .The objective of this study was to analyse the accuracy of calprotectin (compared with APR) in discriminating the clinical disease status of RA patients receiving TCZ.
Methods
A cross-sectional study including all RA patients (ACR 1987 criteria) from our arthritis unit receiving TCZ was carried out. Demographic data, disease duration, autoantibody status (ACPA/RF), radiological data (erosive disease), previous biologic therapy, TCZ treatment duration and dosage (a TCZ dose of 46/kg every 4 weeks was considered a reduced dosage) and concomitant synthetic DMARD therapy, were collected.
Before TCZ administration, all patients underwent a clinical assessment, including 28 swollen and tender joint counts (28-SJC and 28-TJC) and physician and patient global assessment with visual analogue scales (0100 mm). Disease activity indices were subsequently calculated [DAS28-ESR, Simplified Disease Activity Index, (SDAI) and Clinical Disease Activity Index (CDAI)].
In addition, blood samples were obtained just before TCZ administration. ESR was measured using the Westergren method (NV < 20 mm/h), and CRP by nephelometry (lowest detection limit of 0.01 mg/dl; NV < 0.8 mg/ dl). Calprotectin serum levels were determined using an ELISA Test Kit [CALPROLAB Calprotectin ELISA (ALP) CALPRO AS, Norway] in accordance with the manufacturer's protocol. Briefly, 100 ml of each standard, control and diluted 1:20 sample in duplicate wells were incubated at room temperature for 40 min; three washings were made, 100 ml of the conjugated enzyme were added and then plates were incubated at room temperature for 40 min. After three washes and addition of the enzyme substrate, the optical density values at 405 nm were determined using an ELISA reader. To reduce variation in calprotectin determination, the whole procedure was performed in a Triturus autoanalyzer; the coefficients of variation were 5% within and 13% between assays. Serum calprotectin levels were also measured in 40 healthy blood donors. Serum TCZ trough levels were detected by bridging ELISA (LISA-TRACKER Duo Tocilizumab, LTT005 (Theradiag, Croissy-Beaubourg, France)), according to the product insert, with 1 mg/ml the lower level of quantification.
Continuous data were presented as mean (S.D.), and categorical variables as absolute frequency with percentage. Normality was tested with skewness tests and bin-graphs, and the data for most variables were normal or very close to a normal distribution. Groups were compared using the Student's t-test or MannWhitney test when appropriate. Correlations were assessed using Pearson's correlation coefficient. Linear regression models were used to assess the association between calprotectin and DAS28-ESR. Multivariate models were constructed to analyse the effect of covariates, and to fully adjust the association between calprotectin and DAS28. The discriminatory capacity of calprotectin was analysed using receiver operating characteristic curves with activity yes/no (no: DAS28 43.2) as the gold standard, and the best cut-off in terms of sensitivity, specificity and likelihood ratios was identified. The area under the curve was calculated using Hanley's corrected CIs. The odds ratio for the best cut-off of calprotectin was calculated. The analysis was made using STATA version 11 (STATA Corp, College Station, TX, USA). The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee of the Hospital Clinic of Barcelona [Clinical Research Ethics Committee of the Hospital Clínic de Barcelona (CEIC Hospital Clínic)]. Informed consent was obtained from all patients before study enrolment.
Results
A total of 33 patients were included, of whom 91% were female, with a mean age of 53 years. Mean disease duration was 15 years, 67% were RF or ACPA positive, 79% had erosive disease, 70% had previously received biologic therapy, 79% had received concomitant treatment with synthetic DMARDs (mostly MTX) and 57% low doses of glucocorticoids (mean prednisone dose 2.3 mg/day). The mean time of TCZ therapy was 26 months (S.D. 15), and 48.5% of patients had received a low dosage. Remission (DAS28 42.6) and low disease activity (DAS28 2.63.2) were observed in 11 (33%) and 13 (39%) patients, respectively (supplementary Table S1 available at Rheumatology Online).
Serum calprotectin levels were higher in RA patients than in healthy controls [3.20 mg/ml (S.D. 2) vs 1.5 mg/ml (S.D. 0.8), P = 0.001]. Calprotectin levels did not differ according to age or sex and correlated strongly with all composite disease activity indices (Fig. 1AC ) and the 28 SJC/ TJC (Fig. 1J and K) . Adjusted analysis showed a significant association between serum calprotectin levels and DAS28 according to a number of covariates (combined therapy, reduced dose, use of glucocorticoids, disease duration and presence of autoantibodies or erosive disease). Backward selection of variables did not substantially modify the association between calprotectin and DAS28 (supplementary Table S2 CRP and ESR were moderately correlated with DAS28-ESR ( Fig. 1D and G ), but not with SDAI ( Fig. 1E and H) , CDAI ( Fig. 1G and I ) or joint counts (Fig. 1LO) . Calprotectin levels were significantly lower in patients with low disease activity or remission compared with those with moderate/high disease activity, according to all articular indices analysed; however, CRP and ESR identified disease activity status according to the DAS28 but not to the SDAI or CDAI (Table 1) Serum trough TCZ levels did not correlate with disease activity indices, APR or calprotectin. Nineteen (58%) patients had detectable serum trough TCZ levels (51 mg/ml). 
Discussion
Our results show that calprotectin seems to be a good biomarker for the assessment of disease activity in RA patients receiving TCZ, and is apparently more accurate than APR. The dramatic effect of TCZ on APR, markedly decreasing CRP levels, is established [11] . The pronounced effects of TCZ on APR might lead to an overestimation of the response rate when disease activity indices that include APR, such as the DAS/DAS28 or SDAI, are used. In RA patients receiving TCZ, higher rates of remission were obtained using the DAS28 than using the CDAI or SDAI, due to the high weighting of ESR in the DAS28 score [6] . The DAS28 overestimates the rates of remission in RA patients treated with TCZ in comparison with the CDAI, which does not include APR [12] .
We not uncommonly observe patients with a pronounced reduction in CRP or ESR values after TCZ therapy, accompanied by persistent disease activity as shown by a high swollen joint count. Ten of our 24 patients (42%) had very low CRP serum levels (<0.2 mg/dl) accompanied by a swollen joint count of 52. CRP and ESR were only weakly correlated with the DAS28; no correlation between APR and SDAI/CDAI or SJC/TJC was found. Neither ESR nor CRP discriminates between clinical disease activity states, such as remission or low disease activity. Therefore, APRs may not be sensitive biomarkers for the accurate assessment of disease activity in RA patients receiving TCZ. This is the first study to analyse serum calprotectin levels in patients receiving TCZ. Studies have shown that serum calprotectin levels correlate with disease activity in RA [13] , and other inflammatory conditions [1416] and that decreases in serum calprotectin levels after TNF inhibition are sensitive to change [17] , and predict radiographic progression [18] . Our results show that calprotectin correlates better with all disease articular indices and joint counts, independently of covariates, than APR. Calprotectin seems to accurately discriminate between disease activity states, including remission and low disease activity.
Pharmacokinetic studies of TCZ show that a significant proportion of RA patients have undetectable serum trough TCZ levels [19] , as confirmed by our results. Nishimoto et al. [20] found that TCZ normalized CRP values in RA patients as long as free TCZ remained above 1 mg/ml in serum [20] ; in contrast; we found that serum calprotectin levels were independent of detectable serum trough TCZ levels.
Our study has some limitations, including the small sample size and the cross-sectional design, which make it difficult to ascertain the exact effects of TCZ on serum calprotectin levels and their sensitivity to change, as previously reported after TNF antagonist therapy [17] . Moreover, although we tried to find a cut-off point to discriminate active from low disease activity/remission, this would require prospective studies with a large sample size. In summary, serum calprotectin levels may accurately help stratify disease activity in RA patients receiving TCZ. Calprotectin strongly correlated with composite joint indices, whereas there was a weak or no correlation with APR. Calprotectin levels seem to distinguish between patients in remission or with low disease activity, despite the recognized reduction in APR observed after TCZ treatment, independently of serum trough TCZ levels. Calprotectin levels could be considered an accurate biomarker for the assessment of disease activity in RA patients receiving TCZ.
